Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Charles Bengtson, MD, MSc
University of Kansas Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Kansas Medical Center
Kansas City, Kansas, United States
Andreas Schmid, M.D.Matthias Salathe, M.D.Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Jun 2024
- Primary completion
- 31 May 2027
- Completion
- 31 Oct 2027
- Last update posted
- 2 May 2025
- Registered enrollment
- 42
- Registry id
- NCT06364176
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.